fr   en
Clinical Studies

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-01-04
Phase: II
Anouncement: Launch
Biotech: Intercell (Austria)
Pharma:
Product: Travelers' Diarrhea (TD) Vaccine Patch The TD vaccine system consists of a self-adhesive patch containing the vaccine antigen, the LT (heat-labile toxin) from E. coli, and a single-use device used to prepare the skin at the site of patch administration, the Skin Preparation System (SPS).
Disease: Travelers' Diarrhea
Country: UK, Germany
Other: Intercell starts an additional efficacy trial for its patch'based investigational Travelers’ Diarrhea Vaccine System in Asia. This placebo controlled field study with vaccinated travelers from the EU to India will test the efficacy of its TD vaccine.
The primary objective of this clinical trial is prevention of all moderate/severe diarrheal cases
in which LT, LT/ST or ST toxins (ETEC) are detected. The trial will enroll approximately 800
travelers from the UK and Germany.